Table 1.
Clinical characteristics of MS patients.
| Characteristics | Number of patients, mean ± SD or median (IQR) |
|---|---|
| Demographics | |
| Number of patients | 46 |
| Disease duration (years) | 12.5 (8.75–15.25) |
| Age at onset (years) | 30.9 ± 9.1 |
| Sex (male/female) | 14/32 |
| Years between CSF examination and MRI | 10.1 ± 2.0 |
| Disease type (number of patients) | |
| PPMS | 5 (11%) |
| SPMS | 10 (22%) |
| RRMS | 31 (67%) |
| EDSS | |
| At time of CSF examination | 2(1.5–2.375) |
| At time of MRI | 2(1–5.875) |
| DMT at the time of MRI | |
| None | 14 (30%) |
| Interferon-beta | 11 (24%) |
| Fingolimod | 4 (9%) |
| Dimethyl fumarate | 4 (9%) |
| Teriflunomide | 4 (9%) |
| Glatiramer acetate | 7 (15%) |
| Other (alemtuzumab, ocrelizumab, azathioprine) | 2 (4%) |
Normally distributed data are reported as mean ± SD, non-normally distributed data are reported as median (25–75% interquartile range).
PPMS primary-progressive multiple sclerosis, SPMS secondary-progressive multiple sclerosis, RRMS relapsing–remitting multiple sclerosis, EDSS expanded disability status scale, CSF cerebrospinal fluid, DMT disease modifying therapy.